Compare Lumen Technologies Inc (LUMN) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lumen Technologies Inc vs Organon & Co. Common Stock — how do they compare? Lumen Technologies Inc trades at $4.48 (market cap $5.14B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Lumen Technologies Inc is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Lumen Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lumen Technologies Inc for 40 Days and Organon & Co. Common Stock for 0 Days on average.
| LUMN | OGN | |
|---|---|---|
Market Cap | $5.14B | $3.62B |
Volume | 15,538,010 | 2,892,999 |
Sector | Media | Health |
52-Week High | $11.83 | $13.81 |
52-Week Low | $4.55 | $5.70 |
Typical Hold Time | 40 Days | 0 Days |
Enterprise Value | $16.76B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LUMN stock trades at $4.55, down 9.9% in the past 24 hours, reflecting bearish technical signals and negative investor sentiment. The company reported mixed quarterly earnings, with a Q1 2026 miss but a Q2 2026 beat, while full-year 2025 revenue declined to $12.40B with a net loss of $1.74B. High debt levels and a negative ROE of -78.94% highlight financial strain, though recent strategic moves include a Nasdaq listing and new AI-focused networking services to drive growth.
The outlook remains challenging due to persistent losses and heavy debt, but deep value metrics like a low P/S of 0.42 and strategic pivots to AI connectivity offer speculative upside. Key risks include execution on growth initiatives, competitive pressures, and interest rate sensitivity. Analysts are largely cautious, with a 'Reduce' consensus, suggesting limited near-term catalysts.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
